コンテンツへスキップ
Merck
  • HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.

Head & neck (2013-10-15)
J Hun Hah, Mei Zhao, Curtis R Pickering, Mitchell J Frederick, Genevieve A Andrews, Samar A Jasser, David R Fooshee, Zvonimir L Milas, Chad Galer, Daisuke Sano, William N William, Edward Kim, John Heymach, Lauren A Byers, Vali Papadimitrakopoulou, Jeffrey N Myers
要旨

The purpose of this study was to identify mechanisms of innate resistance to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of head and neck squamous cell carcinoma (HNSCC) cell lines. Specifically, we analyzed the role of HRAS mutations in erlotinib resistance. Erlotinib sensitivity was determined by methyl thiazolyl-tetrazolium (MTT) assays. Molecular signaling pathways and somatic mutations were examined. Changes in sensitivity after modulation of HRAS expression were evaluated. All 7 cell lines were wild-type for EGFR and KRAS regardless of erlotinib sensitivity; however, 1 erlotinib-resistant cell line (HN31) harbored an HRAS G12D mutation. Downregulation of HRAS expression by small interfering RNA (siRNA) or short hairpin RNA (shRNA) in HN31 led to increased erlotinib sensitivity in vitro and in vivo. Transfection of activating HRAS-mutant (G12D and G12V) constructs into erlotinib-sensitive cell lines made them more resistant to erlotinib. Activating HRAS mutations can confer erlotinib resistance in an HRAS mutant HNSCC cell line.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ジメチルスルホキシド, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
ジメチルスルホキシド, ACS reagent, ≥99.9%
Sigma-Aldrich
ジメチルスルホキシド, for molecular biology
Sigma-Aldrich
ジメチルスルホキシド, suitable for HPLC, ≥99.7%
Sigma-Aldrich
ジメチルスルホキシド, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
ジメチルスルホキシド, ReagentPlus®, ≥99.5%
Sigma-Aldrich
ジメチルスルホキシド, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
ジメチルスルホキシド, puriss. p.a., ACS reagent, ≥99.9% (GC)
Sigma-Aldrich
ジメチルスルホキシド, anhydrous, ≥99.9%
Sigma-Aldrich
ジメチルスルホキシド, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
ジメチルスルホキシド, puriss. p.a., dried, ≤0.02% water
Sigma-Aldrich
ジメチルスルホキシド, PCR Reagent
Sigma-Aldrich
ジメチルスルホキシド, meets EP testing specifications, meets USP testing specifications
USP
ジメチルスルホキシド, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
ジメチルスルホキシド 溶液, 50 wt. % in H2O
Supelco
ジメチルスルホキシド, analytical standard
Sigma-Aldrich
ジメチルスルホキシド, ≥99.5%
Sigma-Aldrich
ジメチルスルホキシド, JIS special grade, ≥99.0%
Supelco
ジメチルスルホキシド, for inorganic trace analysis, ≥99.99995% (metals basis)
Sigma-Aldrich
ジメチルスルホキシド, suitable for HPLC
Sigma-Aldrich
ジメチルスルホキシド, Vetec, reagent grade, 99%
Sigma-Aldrich
ジメチルスルホキシド, SAJ first grade, ≥99.0%
ジメチルスルホキシド, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
ジメチルスルホキシド, ≥99.0%, suitable for absorption spectrum analysis
Sigma-Aldrich
MISSION® esiRNA, targeting human HRAS
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Hras1